Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Gains from Sales and Divestitures (2016 - 2021)

Historic Gains from Sales and Divestitures for ImmunityBio (IBRX) over the last 7 years, with Q2 2021 value amounting to $336084.0.

  • ImmunityBio's Gains from Sales and Divestitures fell 3987.51% to $336084.0 in Q2 2021 from the same period last year, while for Jun 2021 it was $336084.0, marking a year-over-year decrease of 3987.51%. This contributed to the annual value of $648336.0 for FY2020, which is 6411.45% up from last year.
  • As of Q2 2021, ImmunityBio's Gains from Sales and Divestitures stood at $336084.0, which was down 3987.51% from $235725.0 recorded in Q1 2021.
  • ImmunityBio's Gains from Sales and Divestitures' 5-year high stood at $648336.0 during Q4 2020, with a 5-year trough of $6625.0 in Q1 2017.
  • Over the past 5 years, ImmunityBio's median Gains from Sales and Divestitures value was $172330.0 (recorded in 2018), while the average stood at $234234.9.
  • As far as peak fluctuations go, ImmunityBio's Gains from Sales and Divestitures crashed by 9304.07% in 2017, and later skyrocketed by 95962.26% in 2018.
  • Quarter analysis of 5 years shows ImmunityBio's Gains from Sales and Divestitures stood at $244209.0 in 2017, then fell by 29.43% to $172330.0 in 2018, then skyrocketed by 129.24% to $395051.0 in 2019, then skyrocketed by 64.11% to $648336.0 in 2020, then tumbled by 48.16% to $336084.0 in 2021.
  • Its Gains from Sales and Divestitures stands at $336084.0 for Q2 2021, versus $235725.0 for Q1 2021 and $648336.0 for Q4 2020.